Cardiac Asthma Treatment in India

Cardiac asthma treatment in India from $1,500. Management of heart failure causing breathing difficulty at Apollo, Medanta, Fortis. Expert cardiologists. Book a free consultation today.

Estimated cost: $1,500 – $4,000 · Average stay: 3–7 days

Cardiac asthma is a clinical syndrome of breathlessness, wheezing, and coughing caused by left heart failure rather than primary lung disease (bronchial asthma). When the left ventricle fails to pump blood efficiently, pressure backs up into the pulmonary veins and capillaries, causing fluid to leak from the bloodstream into the lung tissue (pulmonary oedema). This fluid accumulation in the airways and lung parenchyma produces the classic triad of cardiac asthma: breathlessness at rest or with minimal exertion; a characteristic nocturnal breathlessness (paroxysmal nocturnal dyspnoea — PND) that wakes the patient from sleep; and orthopnoea (inability to lie flat, requiring multiple pillows or sleeping in a chair).

The wheezing of cardiac asthma occurs because peribronchial oedema and bronchial wall swelling narrows the small airways — producing airflow obstruction indistinguishable on auscultation from bronchial asthma. This diagnostic confusion is common and potentially dangerous: treating cardiac asthma with beta-2 agonist inhalers (as if it were bronchial asthma) can worsen cardiac function, while treating bronchial asthma with high-dose diuretics would dangerously dehydrate the patient. The correct distinction requires ECG, chest X-ray, B-type natriuretic peptide (BNP) measurement, and echocardiography.

Cardiac asthma is a manifestation of heart failure — it is not a separate disease, but a presentation of the underlying cardiac pathology that must be identified and treated. Common causes include: ischaemic heart disease (heart failure from previous heart attacks); hypertensive heart disease; dilated cardiomyopathy; valvular heart disease (particularly mitral stenosis — which acutely backs pressure into the pulmonary circulation); and acute coronary syndromes.

India's cardiologists at Apollo Hospitals, Medanta – The Medicity, Max Hospital, Fortis, and Kokilaben Dhirubhai Ambani Hospital are expert in differentiating and treating cardiac asthma, offering comprehensive heart failure management programs including drug optimization, device therapy (CRT pacemakers, ICDs), and valvular interventions at a fraction of Western costs.

What is Cardiac Asthma and How Does it Differ from Bronchial Asthma?

The fundamental distinction: bronchial asthma is a primary inflammatory lung disease; cardiac asthma is a consequence of left heart failure causing pulmonary oedema. Both produce wheezing and breathlessness, but the mechanisms and treatments are entirely different.

Key distinguishing features of cardiac asthma:

History: typically older patients with a history of heart disease (ischaemic heart disease, hypertension, heart failure, valvular disease), not the younger allergy/atopy history of bronchial asthma. Symptoms worsen lying flat (orthopnoea) and at night (PND) — bronchial asthma worsens with exercise, cold air, and allergen exposure.

Physical examination: elevated jugular venous pressure (JVP); bilateral basal crackles (sounds of fluid in the lung bases — not heard in uncomplicated bronchial asthma); third heart sound (S3 gallop); peripheral oedema.

Investigations: chest X-ray shows pulmonary vascular redistribution (upper lobe venous engorgement), Kerley B lines, alveolar shadowing (bilateral perihilar "bat-wing" shadow in acute pulmonary oedema), cardiomegaly, and pleural effusions. BNP above 100 pg/mL (or NT-proBNP above 300 pg/mL) strongly supports heart failure. Echocardiography identifies the structural cardiac cause (reduced ejection fraction, diastolic dysfunction, valvular disease). Peak flow and spirometry may show reversible obstructive defect — can overlap with COPD.

Who Has Cardiac Asthma?

Cardiac asthma occurs in patients with underlying left heart disease. The most common at-risk groups are: patients with known heart failure (HFrEF — reduced ejection fraction, or HFpEF — preserved ejection fraction); patients with a history of heart attacks (ischaemic cardiomyopathy); elderly patients with hypertensive heart disease; patients with significant mitral stenosis or aortic stenosis; and patients with new or worsening cardiomyopathy from any cause.

Patients presenting with new-onset wheezing and breathlessness who are older than 50, have cardiovascular risk factors (hypertension, diabetes, ischaemic heart disease), and do not have a history of atopy or allergies should be promptly evaluated for cardiac asthma with BNP and echocardiography. The clinical consequences of misdiagnosis are severe in both directions.

How is Cardiac Asthma Treated?

Acute cardiac asthma (pulmonary oedema) is a medical emergency requiring urgent treatment to prevent respiratory failure and death. Immediate management:

High-flow oxygen; sitting the patient upright to reduce pulmonary venous pressure; intravenous loop diuretics (furosemide 40–80 mg IV — produces rapid diuresis, reducing circulating volume and pulmonary venous pressure within 15–30 minutes); IV morphine (reduces sympathetic drive and pre-load); IV nitrates (glyceryl trinitrate infusion) for rapid venodilation if blood pressure allows; CPAP or BiPAP (non-invasive ventilation) for severe cases not responding to initial medical therapy; and intubation and mechanical ventilation as last resort.

The underlying cardiac cause must then be identified and treated: coronary revascularization (PCI or CABG) for ischaemic cardiomyopathy; optimal heart failure pharmacotherapy (ACE inhibitors/ARBs/ARNIs like sacubitril-valsartan, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors — the "four pillars" of heart failure therapy); cardiac resynchronization therapy (CRT-D pacemaker) for heart failure with wide QRS (dyssynchrony); ICD for high sudden-death risk; and valvular intervention (mitral valve repair/replacement, TAVR for aortic stenosis) for valve-related heart failure.

Chronic cardiac asthma management optimizes diuretic therapy (lowest effective dose to maintain euvolaemia), optimizes neurohormonal blockade, monitors lung function, educates the patient in daily weight measurement, and provides a clear action plan for early symptom deterioration.

Procedure Steps

1. Acute assessment: ABG (arterial blood gas) for oxygenation; 12-lead ECG; chest X-ray; BNP/NT-proBNP; renal function and electrolytes; echocardiogram if available.
2. Immediate treatment: upright positioning; high-flow oxygen (target SpO2 94–98%); IV furosemide; IV nitrates if SBP above 110 mmHg; CPAP/BiPAP for moderate-severe respiratory distress.
3. Monitoring: continuous oxygen saturation; ECG monitoring; urine output hourly; blood pressure 15-minutely.
4. Echocardiography: once stabilized — identifies left ventricular systolic/diastolic dysfunction, valvular disease, pericardial effusion.
5. Coronary angiography: if ACS (acute coronary syndrome) is the precipitant of acute pulmonary oedema — urgent PCI may be required.
6. Chronic heart failure optimization: initiate or uptitrate ACEI/ARB/ARNI, beta-blocker, MRA, SGLT2 inhibitor; titrate diuretic to euvolaemia.
7. Device assessment: CRT-D for LVEF below 35%, LBBB QRS above 130 ms; ICD alone for LVEF below 35% with non-LBBB morphology.
8. Valvular assessment: echo-guided valve assessment; referral for valvular intervention if indicated.
9. Patient education: daily weight monitoring; low-sodium diet; fluid restriction; action plan for weight gain above 2 kg.

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

United States — $5,000 – $20,000 (acute admission and workup) — Baseline

United Kingdom — $3,000 – $10,000 — ~45% savings vs. USA

India — $1,500 – $4,000 — Up to 80% savings vs. USA

UAE — $3,000 – $8,000 — ~60% savings vs. USA

Cardiac asthma management packages in India include emergency acute management (diuresis, CPAP if needed), specialist cardiology review, echocardiogram, BNP, ECG, chest X-ray, coronary angiography if indicated, and optimization of chronic heart failure pharmacotherapy. Device therapy (CRT-D, ICD) and valvular interventions are separately priced as additional packages. Gaf Healthcare helps coordinate both acute and planned chronic heart failure management programs.

Recovery & Follow-up

Acute cardiac asthma resolves rapidly with appropriate diuresis — patients typically notice dramatic improvement in breathing within 30–60 minutes of IV furosemide administration. A 3–7 day hospital stay allows optimization of oral diuretics, ACE inhibitor/ARB introduction, and echocardiographic assessment of the underlying cause.

Chronic cardiac asthma management is a lifelong process. With optimal therapy (four pillars of heart failure: ACEI/ARNI + beta-blocker + MRA + SGLT2i), breathlessness improves significantly, exercise tolerance increases, and the risk of hospitalization and death is substantially reduced. Patient education — daily weight monitoring, low-sodium diet, recognizing worsening symptoms — is as important as medication.

Recovery Tips

• Weigh yourself daily first thing in the morning — report a weight gain of more than 2 kg in 48 hours to your doctor immediately.
• Follow a low-sodium diet (under 2,000 mg sodium daily) — excess salt causes fluid retention and worsens pulmonary oedema.
• Take diuretics in the morning rather than evening to avoid overnight urination disrupting sleep.
• Report increasing breathlessness at rest, inability to lie flat, or rapid weight gain immediately.
• Do not stop ACE inhibitors, beta-blockers, or MRAs without medical advice — these medications have documented mortality benefit.
• Vaccinate annually against influenza and pneumococcus — respiratory infections are the leading precipitant of acute decompensated heart failure.

Risks & Complications

Untreated cardiac asthma or acute pulmonary oedema is life-threatening. Appropriately treated, the immediate risk is low. Risks of treatment include: over-diuresis causing electrolyte disturbance (hyponatraemia, hypokalaemia, pre-renal kidney injury); hypotension from nitrate or ACE inhibitor therapy; and respiratory failure requiring intubation (in severe cases not responding to non-invasive ventilation). Long-term prognosis of cardiac asthma depends on the underlying heart failure severity and the availability of appropriate neurohormonal therapy.

Why GAF Healthcare

Gaf Healthcare coordinates comprehensive heart failure assessment and management programs at India's and UAE's leading cardiology centers. For patients with chronic cardiac asthma from unoptimized heart failure, we arrange the complete echocardiographic and hemodynamic assessment, a specialist heart failure cardiologist consultation for pharmacological optimization, and a device therapy assessment (CRT-D/ICD) when indicated — all within a structured 5–7 day assessment visit.

Frequently Asked Questions

How do I know if my breathing difficulty is cardiac or lung-related?

Key indicators of cardiac asthma: unable to lie flat; worse at night; legs swollen; history of heart disease or hypertension; BNP elevated on blood test; echocardiogram shows impaired heart function. Key indicators of bronchial asthma: history of allergy/atopy; worse with exercise or cold air; improves with bronchodilator inhaler; normal cardiac function on echo.

Can cardiac asthma be cured?

The underlying heart failure causing cardiac asthma cannot always be cured, but it can be dramatically improved with modern therapy. Patients with ischaemic cardiomyopathy who receive revascularization, and patients with valvular disease who receive valve repair or replacement, often see significant recovery of heart function and resolution of pulmonary congestion.

What is the best treatment for cardiac asthma?

The immediate treatment is IV diuretics (furosemide) to rapidly remove excess fluid. The long-term treatment is optimizing the four pillars of heart failure therapy: ACE inhibitor/ARNI (sacubitril-valsartan), beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor — each proven to reduce mortality and hospitalizations in heart failure with reduced ejection fraction.